JP5371443B2 - 亜塩素酸塩製剤、およびこの調製の方法と利用 - Google Patents

亜塩素酸塩製剤、およびこの調製の方法と利用 Download PDF

Info

Publication number
JP5371443B2
JP5371443B2 JP2008547585A JP2008547585A JP5371443B2 JP 5371443 B2 JP5371443 B2 JP 5371443B2 JP 2008547585 A JP2008547585 A JP 2008547585A JP 2008547585 A JP2008547585 A JP 2008547585A JP 5371443 B2 JP5371443 B2 JP 5371443B2
Authority
JP
Japan
Prior art keywords
chlorite
formulation
variations
formulations
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008547585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521473A5 (enExample
JP2009521473A (ja
Inventor
ボーランジヤー，ウイリアム
アジール，アラステシユ・アリ
Original Assignee
ニューラルタス ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5371443(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューラルタス ファーマシューティカルズ，インコーポレイテッド filed Critical ニューラルタス ファーマシューティカルズ，インコーポレイテッド
Publication of JP2009521473A publication Critical patent/JP2009521473A/ja
Publication of JP2009521473A5 publication Critical patent/JP2009521473A5/ja
Application granted granted Critical
Publication of JP5371443B2 publication Critical patent/JP5371443B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B11/00—Oxides or oxyacids of halogens; Salts thereof
    • C01B11/08—Chlorous acid
    • C01B11/10—Chlorites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Geology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2008547585A 2005-12-22 2006-12-21 亜塩素酸塩製剤、およびこの調製の方法と利用 Active JP5371443B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75349705P 2005-12-22 2005-12-22
US60/753,497 2005-12-22
PCT/US2006/048941 WO2007075972A2 (en) 2005-12-22 2006-12-21 Chlorite formulations, and methods of preparation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013000170A Division JP5860821B2 (ja) 2005-12-22 2013-01-04 亜塩素酸塩製剤、およびこの調製の方法と利用

Publications (3)

Publication Number Publication Date
JP2009521473A JP2009521473A (ja) 2009-06-04
JP2009521473A5 JP2009521473A5 (enExample) 2010-02-12
JP5371443B2 true JP5371443B2 (ja) 2013-12-18

Family

ID=38218646

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008547585A Active JP5371443B2 (ja) 2005-12-22 2006-12-21 亜塩素酸塩製剤、およびこの調製の方法と利用
JP2013000170A Expired - Fee Related JP5860821B2 (ja) 2005-12-22 2013-01-04 亜塩素酸塩製剤、およびこの調製の方法と利用
JP2014165700A Withdrawn JP2014210817A (ja) 2005-12-22 2014-08-18 亜塩素酸塩製剤、およびこの調製の方法と利用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013000170A Expired - Fee Related JP5860821B2 (ja) 2005-12-22 2013-01-04 亜塩素酸塩製剤、およびこの調製の方法と利用
JP2014165700A Withdrawn JP2014210817A (ja) 2005-12-22 2014-08-18 亜塩素酸塩製剤、およびこの調製の方法と利用

Country Status (6)

Country Link
US (5) US8067035B2 (enExample)
EP (1) EP1979269A4 (enExample)
JP (3) JP5371443B2 (enExample)
AU (1) AU2006331497B2 (enExample)
CA (2) CA2634915A1 (enExample)
WO (1) WO2007075972A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027330A1 (en) * 2005-03-01 2011-02-03 Martin Roy W Tablet composition for the in-situ generation of chlorine dioxide for use in antimicrobial applications
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
WO2008145376A1 (en) * 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
CA2807723A1 (en) * 2010-08-13 2012-02-16 Servet Buyuktimkin Foamable compositions of stabilized chlorite
FR2968559B1 (fr) 2010-12-14 2012-12-28 Alexandra Fregonese Nouvelles compositions a base d'argile et de beepollen, leur procede de preparation et leurs utilisations en nutrition et en therapeutique
DE102010055771A1 (de) * 2010-12-23 2012-06-28 KyroChem GmbH Chlorithaltige Zusammensetzung
WO2012106822A1 (en) * 2011-02-09 2012-08-16 Nuvo Research Ag. Wound dressings comprising chlorite
US9381214B2 (en) 2011-03-18 2016-07-05 Puricore, Inc. Methods for treating skin irritation
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN104519890A (zh) * 2012-01-19 2015-04-15 Ibt美国公司 四氯十氧(tcdo)的治疗应用
JP2015071581A (ja) * 2013-05-20 2015-04-16 本部三慶株式会社 亜塩素酸水含有ウイルス殺傷剤
CN105637189B (zh) * 2013-10-03 2021-11-16 优美科股份公司及两合公司 废气后处理系统
WO2015181800A2 (en) * 2014-05-30 2015-12-03 Nuvo Research Ag Methods for purifying chlorites and chlorates
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
DE102016007081A1 (de) * 2016-06-10 2017-12-14 Alethia Life Sciences Ag Chlordioxid Desinfektionstuch
JP7071777B2 (ja) * 2020-05-21 2022-05-19 国立大学法人大阪大学 上皮癌治療薬
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
JP2025518546A (ja) 2022-05-19 2025-06-17 ニューヴィヴォ， インコーポレイテッド 神経変性疾患のバイオマーカー
WO2024220617A2 (en) * 2023-04-20 2024-10-24 Neuvivo, Inc. Chlorite compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2129464A (en) * 1937-10-06 1938-09-06 Mathieson Alkali Works Inc Recovery of sodium chloride and sodium chlorite from aqueous solutions
US2169066A (en) 1938-07-01 1939-08-08 Mathieson Alkali Works Inc Preparation of sodium chlorate and sodium chlorite and the separation thereof
DE941665C (de) * 1951-04-19 1956-04-19 Val Mehler Segeltuchweberei Ag Verfahren zum Bleichen von Textilien
US3082146A (en) 1959-02-04 1963-03-19 Chemical Res Lab Of America In Process for the treatment of water
US4296103A (en) 1980-08-08 1981-10-20 Felipe Laso Stabilized solution of chlorine oxides
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
DE3515748A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer isotonen chloritmatrix-loesung bei der behandlung von tumoren
DE3515749A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US4944920A (en) 1986-08-01 1990-07-31 University Of Southern California Novel method to treat blood
US4851222A (en) 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US5078908A (en) * 1989-10-02 1992-01-07 Allergan, Inc. Methods for generating chlorine dioxide and compositions for disinfecting
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5622725A (en) * 1992-03-20 1997-04-22 Alcide Corporation Wound disinfection and repair
GB9208731D0 (en) * 1992-04-22 1992-06-10 Squibb & Sons Inc Hydrocolloid wound gel
US5830511A (en) 1992-06-25 1998-11-03 Bioxy Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US6099855A (en) 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
AU676528B2 (en) 1992-12-17 1997-03-13 Advanced Medical Optics, Inc. Contact lens disinfecting solution containing sodium chlorite and polyvinyl pyrrolidone
JPH06230717A (ja) 1993-02-02 1994-08-19 Kanebo Ltd 骨模型
US5639295A (en) * 1995-06-05 1997-06-17 Southwest Research Institute Method of making a composition containing a stable chlorite source
US5489435A (en) * 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5723095A (en) * 1995-12-28 1998-03-03 Steris Corporation Cleaner concentrate formulation for biological waste fluid handling systems
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
AU754928B2 (en) 1997-10-06 2002-11-28 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US6132702A (en) * 1998-02-27 2000-10-17 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
AU6416999A (en) 1998-10-08 2000-04-26 Hampar L. Karagoezian Synergistic antimicrobial, dermatological and ophthalmic preparations containingchlorite and hydrogen peroxide
US20040037891A1 (en) * 1999-10-04 2004-02-26 Karagoezian Hampar L. Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide
US20040224306A1 (en) 1999-11-30 2004-11-11 Frederich-Wilhelm Kuhne Evaluating and predicting clinical outcomes by gene expression analysis
DE10012340A1 (de) * 2000-03-14 2001-09-20 Merck Patent Gmbh Verfahren zur Baeyer-Villiger-Oxidation organischer Carbonylverbindungen
WO2003025252A1 (en) * 2001-01-16 2003-03-27 Kelley Joseph M An electrolytic process for the generation of stable solutions of chlorine dioxide
AU2002311922A1 (en) * 2001-05-15 2002-11-25 The Procter And Gamble Company Oral care compositions
ITMI20011702A1 (it) * 2001-08-03 2003-02-03 Acraf Soluzione disinfettante a base di ipoclorito di sodio e procedimento per prepararla
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
CN107074497B (zh) 2014-09-09 2019-07-05 三菱电机株式会社 电梯的设备安装装置

Also Published As

Publication number Publication date
WO2007075972A2 (en) 2007-07-05
CA2634915A1 (en) 2007-07-05
JP2013100312A (ja) 2013-05-23
US20120015051A1 (en) 2012-01-19
US8231856B2 (en) 2012-07-31
JP2014210817A (ja) 2014-11-13
EP1979269A4 (en) 2013-01-02
US9839650B2 (en) 2017-12-12
US8501244B2 (en) 2013-08-06
WO2007075972A3 (en) 2008-12-04
AU2006331497B2 (en) 2013-07-04
US9266734B2 (en) 2016-02-23
US20160129040A1 (en) 2016-05-12
JP5860821B2 (ja) 2016-02-16
EP1979269A2 (en) 2008-10-15
JP2009521473A (ja) 2009-06-04
US20120021069A1 (en) 2012-01-26
CA2919344A1 (en) 2007-07-05
US8067035B2 (en) 2011-11-29
US20120021070A1 (en) 2012-01-26
US20070145328A1 (en) 2007-06-28
AU2006331497A1 (en) 2007-07-05
CA2919344C (en) 2017-02-28

Similar Documents

Publication Publication Date Title
JP5860821B2 (ja) 亜塩素酸塩製剤、およびこの調製の方法と利用
ES2880500T3 (es) Composiciones farmacéuticas que contienen nitrito de sodio
US7351695B2 (en) Topiramate salts and compositions comprising and methods of making and using the same
US10201519B2 (en) Stabilized pediatric suspension of carisbamate
WO2009021404A1 (en) (1s, 2s, 3s, 4r)-3-[(1s)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2- hydroxyl-cyclopentyl-1-carboxylic acid hydrates and pharmaceutical uses thereof
JP2014520897A (ja) 一酸化ルテニウム放出分子およびその使用
AU2013234421B2 (en) Chlorite formulations, and methods of preparation and use thereof
US20250197398A1 (en) Varenicline Related Compounds and Methods for Treating Diseases and Conditions Including Tobacco Use Disorder
AU2015255176A1 (en) Chlorite formulations, and methods of preparation and use thereof
EP4702977A1 (en) Uric acid transporter agonist compound, pharmaceutical composition, and preparation method therefor and use thereof
WO2013019611A1 (en) Denibulin di-hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120927

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130104

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20130104

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130917

R150 Certificate of patent or registration of utility model

Ref document number: 5371443

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250